Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 6/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9920883 | 0.90 | ALDH1A1 (0.47) | ALDH1A1GSK3BKCNH2POLBDGAT2 | |
| SCHEMBL9920885 | 0.88 | ACKR3 (0.37) | ALDH1A1 | |
| SCHEMBL9920822 | 0.88 | HDAC6 (0.36) | ALDH1A1 | |
| SCHEMBL18558524 | 0.86 | MEN1 (0.35) | ALDH1A1 | |
| SCHEMBL9921025 | 0.85 | HDAC6 (0.39) | ALDH1A1GSK3BKCNH2DGAT2 | |
| SCHEMBL18558525 | 0.85 | DYRK1A (0.34) | ALDH1A1GSK3BSCN9A | |
| SCHEMBL19041504 | 0.84 | HDAC6 (0.32) | — | |
| SCHEMBL9921024 | 0.83 | GSK3B (0.38) | GSK3BKCNH2 | |
| SCHEMBL9920869 | 0.81 | NPC1 (0.42) | KCNH2POLB | |
| SCHEMBL9920911 | 0.81 | NPC1 (0.39) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932313-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170267643-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-09-21 | — | — | US | disclosed |
| EP-2648511-B1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORP (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9580388-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9139532-B2 | Pyrazolyl guanidine F1F0-atpase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2015-09-22 | — | — | US | disclosed |
| WO-2012078874-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267643-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5F1D, ATP5ME | ALDH1A1 2132/4885GSK3B 4597/4885KCNH2 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.